ELE:BMEEndesa S.A. Analysis
Data as of 2026-03-14 - not real-time
$22.37
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Elemental Royalty Corporation is trading above its 20‑day and 50‑day simple moving averages, signalling a bullish price bias despite a modest RSI hovering just above the neutral 50 level. Technical momentum remains positive as the 200‑day SMA sits well below the current price, while volume has been on an upward trend, supporting the price advance. However, the MACD histogram has turned negative and the signal line is flagged as bearish, suggesting short‑term pressure may resume. Fundamentally, the company posted an 84% revenue surge and maintains an exceptional gross margin near 99%, delivering solid operating cash flow and a debt‑free balance sheet. The recent announcement of a modest cash dividend (US$0.12 per share) – with an innovative option to receive it in tokenized gold – adds a new income stream and underscores confidence in cash generation. Valuation metrics are stretched, with a trailing P/E above 110 and a price‑to‑sales ratio exceeding 40, while a DCF model implies a fair value far below the market price. Nonetheless, analyst consensus targets of $32 imply a potential upside of roughly 40% from current levels. The stock’s beta of 0.25 indicates limited market sensitivity, yet 30‑day volatility remains high at nearly 90%, reflecting commodity price swings. Geographic exposure spans multiple continents, diversifying project risk, but the basic materials sector carries inherent regulatory and commodity‑price uncertainties. In this context, the stock appears positioned for a mid‑term rally if earnings momentum sustains, while short‑term downside risk is bounded by a support near $19.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price trading above short‑term SMAs but MACD turning bearish
- High short‑term volatility
- Support level around $19 limiting downside
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong revenue growth and near‑perfect gross margins
- New dividend program enhancing cash return
- Analyst target price suggesting ~40% upside
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Debt‑free balance sheet and stable royalty cash flows
- Valuation multiples remain elevated relative to fundamentals
- Diversified global royalty portfolio mitigating single‑project risk
Key Metrics & Analysis
Financial Health
Revenue Growth84.20%
Profit Margin15.45%
P/E Ratio111.8
ROE2.84%
ROA2.89%
P/B Ratio2.7
Op. Cash Flow$22.2M
Free Cash Flow$7.9M
Technical Analysis
TrendBullish
RSI51.7
Support$18.90
Resistance$24.64
MA 20$22.34
MA 50$20.75
MA 200$16.35
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88
Valuation
Fair Value$4.84
Target Price$32.00
Upside/Downside43.08%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.25
Volatility89.55%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.